QuidelOrtho reports FY25 revenue $2.73B, adjusted EBITDA $597M; guides FY26 revenue $2.7-2.9B

QuidelOrtho Corp

2025-FY EPS reported -$16.69 revenue$2,730,200,000

FY25 total revenue $2.73B in line with guidance; Labs revenue +6% as reported, non-respiratory +5% ex Donor Screening.
GAAP net loss $1.13B includes $701M goodwill impairment; adjusted diluted EPS $2.12 (in range $2.00-$2.15).
Adjusted EBITDA margin expanded 240 bps to 22%; adjusted EBITDA $597M (in range $585-$605M).
FY26 guidance: revenue $2.7-2.9B, adjusted EBITDA $630-670M (23.3% margin), free cash flow $120-160M.
Q4 revenue $724M, adjusted EBITDA $153M, adjusted EPS $0.46; Labs +8% as reported.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.